Metabolic syndrome research commonly focuses on classical risk factors and reaching widely agreed thresholds (glucose, lipids, blood pressure). LeiCeM takes a different approach by addressing individual factors much earlier in the causality chain such as genetic predisposition and evolutionary heritage, determinants in early life, gender, hormonal transitions such as puberty and menopause, microbiome and epigenetic alterations, and aspects of mental health. The research incorporates many such factors into multi-dimensional analyses in ongoing cohorts to design and conduct proof-of-concept interventions in selected groups such as in patients with high-risk metabolic inflammation or children with specific forms of obesity or early menopausal women with reduced gut microbial diversity.

Personalized Therapies Through Targeted Data Analysis

Using artificial intelligence, LeiCeM will combine trajectories, precision phenotyping, and multi-omics data to create innovative score-based tools for disease detection, monitoring, and assessment of treatment success. These tools will focus on brain and psychosocial health, adipose tissue and liver health, and cardiovascular health (“Organ Health Concept”). These novel scores will be used to design and pilot subgroup-specific intervention studies focusing on response likelihood. Both classical interventions (e.g., drugs, behavior, exercise) and novel therapies (e.g., dietary interventions, microbiome interventions, or tailored cellular therapies) will be tested in clinical trials and cohorts. Our aim is to define subgroup-specific predictors of response (e.g., circulating markers, accessible liquid and solid tissue samples, behavioral traits, imaging patterns). Special emphasis will be placed on the influence of sex and gender on the treatment of metabolic diseases.

New Structures for the Medicine of Tomorrow

Since funding began in January 2026, 30 research projects have already been initiated that address metabolic health from various disciplines and perspectives. By the end of the seven-year funding period in 2032, up to four new professorships will also be established at LeiCeM, along with a training program offering innovative opportunities for medical students and early-career researchers.

The combination of expertise in metabolic, cardiovascular, neuroimaging, and psychometrics in Leipzig creates a unique foundation for further advancing metabolic medicine – even by international standards. After decades of limited progress for millions of people affected by metabolic syndrome, LeiCeM offers a unique opportunity to redefine the future of metabolic medicine.

Involved Institutions:

• Ben-Gurion University of the Negev
• Fraunhofer Institute for Cell Therapy and Immunology (IZI)
• Heart Centre Leipzig GmbH
• Helmholtz Centre for Environmental Research (UFZ)
• Helmholtz Munich – German Research Center for Environmental Health
• Max Planck Institute for Evolutionary Anthropology (MPI EVA)
• Max Planck Institute for Human Cognitive and Brain Sciences